R&D portfolios and pharmaceutical licensing
R&D portfolios and pharmaceutical licensing
复制标题
DOI：
10.1016/j.respol.2014.03.008
复制
发表时间：
2014-09
期刊：
影响因子：
7.2
通讯作者：
J. Nishimura;Yosuke Okada
中科院分区：
文献类型：
--
作者：
J. Nishimura;Yosuke Okada
我们研究了药物管道的研发组合如何影响制药许可，控制公司规模，多样性和竞争。收集的数据包括1997年至2007年期间54家日本制药公司关闭的434个许可证进口和329个许可证出口。我们特别关注特定阶段的许可，将创新过程分为早期和后期阶段。使用看似不相关的回归（SUR）的许可和许可的联合估计显示，药物管道显着影响特定阶段的许可，诱导组合效应，导致平滑的药物管道在早期和后期阶段。
We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competition. The data collected comprises 434 license-ins and 329 license-outs closed by 54 Japanese pharmaceutical companies between 1997 and 2007. We pay special attention to stage-specific licensing by dividing the innovation process into early and late stages. Joint estimates of license-in and license-out using seemingly unrelated regressions (SUR) reveal that drug pipelines significantly affect stage-specific licensing, inducing portfolio effect that lead to smoothing drug pipelines across early and late stages.